Developer docs
API playgroundTry for free, no card

Search company profiles

Augurex Life Sciences

Full company profile

uuid0002h6d

Namestring
Augurex Life Sciences
Legal namestring
Augurex Life Sciences Corp.
Websiteurl
augurex.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Augurex Life Sciences Corp. is a Vancouver, British Columbia-based commercial-stage diagnostics company that develops and commercializes biomarker-driven blood tests for autoimmune conditions, with primary focus on rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The company's core technology is the proprietary 14-3-3eta biomarker platform — a joint-derived intracellular protein that is externalized during joint inflammation and acts as a proinflammatory ligand, driving joint erosion and damage through the FOXO3-Snail axis and downstream production of TNF-α, IL-6, RANKL, and MMP-9. Augurex's product portfolio includes JOINTstat (an ELISA-based blood test measuring 14-3-3eta protein levels for RA diagnosis and monitoring) and SPINEstat (a first-in-class multiplex immunoassay detecting autoantibodies to 14-3-3eta epitopes for axSpA diagnosis), as well as analyte-specific reagents (ASRs) sold to US clinical laboratories for development of their own laboratory-developed tests.

The company operates a B2B diagnostics model, monetizing primarily through licensing/royalty arrangements with major clinical laboratory networks and through ASR reagent sales. In the US, tests are distributed via Quest Diagnostics (under an exclusive license covering 14-3-3eta), Labcorp, ARUP Laboratories, and Sonic Healthcare USA. In Canada, distribution is through Dynacare and MitogenDx. End-user demand is driven by rheumatologist adoption, supported by active participation in major rheumatology conferences (ACR, EULAR, SPARTAN), patient advocacy partnerships, and over 10 years of peer-reviewed clinical evidence spanning 2,000+ evaluated patients. Regulatory clearances include Health Canada approvals for both products, UKCA marking in Great Britain, FDA Breakthrough Device Designation for SPINEstat, ISO 13485:2016 certification, and MDSAP certification.

Augurex is a privately held company with 1-10 employees, founded circa 2011 by Dr. Norma Biln and Dr. Anthony Marotta. In August 2024, veteran life sciences executive Neil Klompas (former President and COO of Zymeworks) was appointed President and CEO, with co-founder Dr. Biln transitioning to Chair of the Board. The company received a $5M CAD grant from PacifiCan (Canadian government) in 2024, and is recognized as Life Sciences BC's 2024 Emerging Company of the Year and a finalist for the ADLM 2026 Disruptive Technology Award.

Short descriptiontext

Augurex Life Sciences is a Vancouver-based diagnostics company that develops and commercializes proprietary 14-3-3eta biomarker blood tests — JOINTstat for rheumatoid arthritis and SPINEstat for axial spondyloarthritis — distributed through major clinical laboratory networks in North America and the UK.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autoimmune disease diagnostics, biomarker blood tests, rheumatoid arthritis testing, axial spondyloarthritis diagnosis, clinical laboratory reagents
Industry4 codes
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Autoimmune Disease Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeLicensing Royalties
Description

Augurex's tests are offered through laboratory partners who perform the testing services. The company generates revenue through analyte-specific reagents (ASRs) sold to clinical laboratories, distribution arrangements, and licensing agreements with major lab networks (Quest, Labcorp, Sonic Healthcare, ARUP).

augurex.com
2Laboratory Developed Tests (LDTs)
TypeHardware Sales
Description

US clinical laboratories purchase Augurex's analyte-specific reagents to develop their own laboratory-developed tests, creating a recurring revenue stream from reagent sales.

augurex.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1JOINTstat
Description

14-3-3eta protein test for diagnosing and monitoring rheumatoid arthritis. Health Canada-approved and UKCA-authorized for RA diagnosis and management.

augurex.com
+1 more record
Core offering1 text field

Augurex develops and commercializes proprietary biomarker-based blood diagnostic tests for autoimmune conditions. The two commercial products are JOINTstat, an ELISA measuring the 14-3-3eta protein for rheumatoid arthritis diagnosis and monitoring, and SPINEstat, a first-in-class Anti-14-3-3eta Multiplex immunoassay for axial spondyloarthritis diagnosis. Augurex also sells 14-3-3eta and Anti-14-3-3eta Multiplex analyte-specific reagents (ASRs) to U.S. clinical laboratories for laboratory-developed test development, and licenses the biomarker to laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP, Sonic Healthcare USA, Dynacare, and MitogenDx.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 93% of early RA patients are positive for 14-3-3eta markers
+5 more records
Product overview1 text field

Augurex Life Sciences is a commercial-stage diagnostics company offering a portfolio of biomarker-driven diagnostic tests for autoimmune conditions. The core products are JOINTstat® (14-3-3eta protein test) for rheumatoid arthritis diagnosis and monitoring, and SPINEstat® (Anti-14-3-3eta Multiplex) for axial spondyloarthritis diagnosis. Both tests are backed by the 14-3-3eta biomarker platform, with analyte-specific reagents (ASRs) also available for U.S. clinical laboratories to develop their own tests. The company operates as a B2B diagnostics provider, selling tests through laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP Laboratories, Sonic Healthcare USA, Dynacare, and MitogenDx.

Product and service4 records
1JOINTstat (14-3-3eta Protein Test)
CategoryAutoimmune Disease Diagnostics - Rheumatoid Arthritis
Description

ELISA-based blood diagnostic test that measures the 14-3-3eta protein for the diagnosis and monitoring of rheumatoid arthritis (RA). Health Canada-approved and UKCA-authorized for RA diagnosis and management, and supported by over 10 years of peer-reviewed clinical evidence. 93% of early RA patients are positive for 14-3-3eta, and 14-3-3eta provides 5 to 50 times greater likelihood of having RA versus healthy controls.

2SPINEstat (Anti-14-3-3eta Multiplex)
CategoryAutoimmune Disease Diagnostics - Axial Spondyloarthritis
Description

First-in-class multiplex immunoassay blood test that detects autoantibodies to 14-3-3eta epitopes for the diagnosis of axial spondyloarthritis (axSpA). Differentiates axSpA from mechanical back pain with AUC 0.82, sensitivity 76.2%, and specificity 74.1%; combination of 14-3-3eta autoantibodies and CRP identifies 90% of AS patients. Health Canada-approved, UKCA-marked, and FDA Breakthrough Device Designation.

314-3-3eta Analyte-Specific Reagents (ASRs)
CategoryAnalyte-Specific Reagents for Clinical Laboratories
Description

Analyte-specific reagents (ASRs) for the 14-3-3eta biomarker available for purchase and use by U.S. clinical laboratories as components of diagnostic tests developed by such laboratories for detecting the 14-3-3eta protein. Distributed to clinical labs to enable laboratory-developed tests for rheumatoid arthritis.

4Anti-14-3-3eta Multiplex ASRs
CategoryAnalyte-Specific Reagents for Clinical Laboratories
Description

Analyte-specific reagents for detecting anti-14-3-3eta autoantibodies, sold to clinical laboratories for development of laboratory-developed tests to aid in the diagnosis of axial spondyloarthritis. Enables broad laboratory adoption of the SPINEstat biomarker through LDTs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-17
Description

Augurex launched its 14-3-3eta test through Sonic Reference Laboratory, a division of Sonic Healthcare USA, for rheumatoid arthritis diagnosis and monitoring. The test became available December 15, 2025, expanding access across the US through Sonic's national laboratory network. Sonic Healthcare serves over 100 million patients annually across eight countries.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-15
Description

Partnership with Calgary-based MitogenDx to expand access to JOINTstat testing across Canada, with particular focus on Alberta. MitogenDx, founded by Dr. Marvin Fritzler (pioneer in rheumatology diagnostics), offers the test through its laboratory network starting January 1, 2026. This partnership enhances access to advanced RA diagnostic testing and disease monitoring for clinicians and patients nationwide.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-15
Description

Exclusive license agreement for development of clinical laboratory-developed testing service for 14-3-3eta biomarker in the US market. Quest offers the 14-3-3eta Protein test (Test Code 91455).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-13
Description

Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs) enabling New Day Diagnostics to develop and offer a first-in-class diagnostic test for axial spondyloarthritis. This partnership expands the availability of SPINEstat testing capabilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-21
Description

ARUP Laboratories launched 14-3-3eta testing to enhance early diagnosis and management of rheumatoid arthritis. Offers both standalone 14-3-3eta Protein test and Early/Established RA Panel combining multiple biomarkers.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Labcorp offers 14-3-3eta testing including standalone 14-3-3eta Protein (504550) and RheumAssure combined panel (504509) which includes RF and anti-CCP markers.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution arrangement for JOINTstat 14-3-3eta RUO (research use only) ELISA, enabling broader access for investigators and pharmaceutical companies to advance research on the joint damage biomarker.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dynacare launched JOINTstat testing services in Canada, making the 14-3-3eta blood test accessible to more physicians and patients across Canada. Dynacare is one of Canada's largest health solution companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine by combining research and development expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche's cobas and Elecsys platforms include autoimmune serology assays (anti-CCP, RF, anti-dsDNA). Comparable as a broad IVD incumbent with rheumatology-adjacent test menus distributed globally.

TypeBroad incumbent
Description

Phadia (ImmunoCAP) and the broader Specialty Diagnostics segment provide allergy and autoimmune IVD solutions at global scale. Comparable as a broad IVD incumbent with overlapping rheumatology and immunology test menus.

TypeBroad incumbent
Description

Siemens Healthineers' Atellica and ADVIA Centaur platforms include autoimmune and inflammation assays. Comparable as a broad IVD incumbent serving rheumatology and reference lab channels.

TypeDirect peer
Description

Werfen's Inova Diagnostics and Binding Site divisions are leaders in autoimmune specialty diagnostics (ANA, anti-CCP, anti-dsDNA, ENA panels). Directly comparable as autoimmune IVD specialty providers serving rheumatology labs.

TypeBroad incumbent
Description

Bio-Rad's Life Science and Clinical Diagnostics segments offer autoimmune and immunology assays (e.g., BioPlex 2200) widely used by rheumatology labs. Comparable as a broad IVD incumbent with overlapping autoimmune diagnostic menu.

6Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ARCHITECT and Alinity platforms run autoimmune and rheumatology assays in high-volume clinical labs. Comparable as a broad IVD incumbent with overlapping autoimmune test offerings.

7Crescendo Bioscience (Myriad Genetics)
TypeDirect peer
Description

Crescendo's Vectra DA is a multi-marker blood test for rheumatoid arthritis disease activity, sold through Myriad Genetics. Directly comparable to JOINTstat as an RA-specific biomarker test distributed via US clinical laboratories and used by rheumatologists.

TypeRegional player
Description

Listed here as a placeholder: regional or specialty autoimmune diagnostic developers (e.g., Aeskulisa, Cambridge Life Sciences, AESKU.GROUP) operate in Europe with comparable autoimmune ELISA and immunoblot reagent portfolios. Comparable as autoimmune-focused specialty IVD developers serving similar lab customers.

TypeEmerging player
Description

Scipher Medicine offers PrismRA, a blood-based molecular signature test for rheumatoid arthritis treatment selection. Comparable as an emerging molecular/blood diagnostics company targeting RA rheumatology prescribing decisions.

10Euroimmun (Revvity / PerkinElmer)
TypeDirect peer
Description

Euroimmun specializes in autoimmune and infection serology diagnostics (ANA, anti-CCP, myositis, vasculitis panels), serving rheumatology laboratories. Highly comparable as an autoimmune-focused IVD specialty company.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Augurex Life Sciences

Autoimmune Disease Diagnosticsaugurex.com

Augurex Life Sciences is a Vancouver-based diagnostics company that develops and commercializes proprietary 14-3-3eta biomarker blood tests — JOINTstat for rheumatoid arthritis and SPINEstat for axial spondyloarthritis — distributed through major clinical laboratory networks in North America and the UK.

What Augurex Life Sciences does

Augurex Life Sciences Corp. is a Vancouver, British Columbia-based commercial-stage diagnostics company that develops and commercializes biomarker-driven blood tests for autoimmune conditions, with primary focus on rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The company's core technology is the proprietary 14-3-3eta biomarker platform — a joint-derived intracellular protein that is externalized during joint inflammation and acts as a proinflammatory ligand, driving joint erosion and damage through the FOXO3-Snail axis and downstream production of TNF-α, IL-6, RANKL, and MMP-9. Augurex's product portfolio includes JOINTstat (an ELISA-based blood test measuring 14-3-3eta protein levels for RA diagnosis and monitoring) and SPINEstat (a first-in-class multiplex immunoassay detecting autoantibodies to 14-3-3eta epitopes for axSpA diagnosis), as well as analyte-specific reagents (ASRs) sold to US clinical laboratories for development of their own laboratory-developed tests.

The company operates a B2B diagnostics model, monetizing primarily through licensing/royalty arrangements with major clinical laboratory networks and through ASR reagent sales. In the US, tests are distributed via Quest Diagnostics (under an exclusive license covering 14-3-3eta), Labcorp, ARUP Laboratories, and Sonic Healthcare USA. In Canada, distribution is through Dynacare and MitogenDx. End-user demand is driven by rheumatologist adoption, supported by active participation in major rheumatology conferences (ACR, EULAR, SPARTAN), patient advocacy partnerships, and over 10 years of peer-reviewed clinical evidence spanning 2,000+ evaluated patients. Regulatory clearances include Health Canada approvals for both products, UKCA marking in Great Britain, FDA Breakthrough Device Designation for SPINEstat, ISO 13485:2016 certification, and MDSAP certification.

Augurex is a privately held company with 1-10 employees, founded circa 2011 by Dr. Norma Biln and Dr. Anthony Marotta. In August 2024, veteran life sciences executive Neil Klompas (former President and COO of Zymeworks) was appointed President and CEO, with co-founder Dr. Biln transitioning to Chair of the Board. The company received a $5M CAD grant from PacifiCan (Canadian government) in 2024, and is recognized as Life Sciences BC's 2024 Emerging Company of the Year and a finalist for the ADLM 2026 Disruptive Technology Award.

Augurex Life Sciences firmographics

Firmographics
Name
Augurex Life Sciences
Legal name
Augurex Life Sciences Corp.
Website
https://augurex.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Augurex Life Sciences is a Vancouver-based diagnostics company that develops and commercializes proprietary 14-3-3eta biomarker blood tests — JOINTstat for rheumatoid arthritis and SPINEstat for axial spondyloarthritis — distributed through major clinical laboratory networks in North America and the UK.
Ownership category
akta.pro rank

Augurex Life Sciences industry classification

Industry
Product category
Autoimmune Disease Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Autoimmune disease diagnostics
  • Biomarker blood tests
  • Rheumatoid arthritis testing
  • Axial spondyloarthritis diagnosis
  • Clinical laboratory reagents

Where Augurex Life Sciences is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Augurex Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. Diagnostic Testing Services: Augurex's tests are offered through laboratory partners who perform the testing services. The company generates revenue through analyte-specific reagents (ASRs) sold to clinical laboratories, distribution arrangements, and licensing agreements with major lab networks (Quest, Labcorp, Sonic Healthcare, ARUP).
  2. Laboratory Developed Tests (LDTs): US clinical laboratories purchase Augurex's analyte-specific reagents to develop their own laboratory-developed tests, creating a recurring revenue stream from reagent sales.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels4 records

Augurex Life Sciences product offering

Product offering

Core offering

Augurex develops and commercializes proprietary biomarker-based blood diagnostic tests for autoimmune conditions. The two commercial products are JOINTstat, an ELISA measuring the 14-3-3eta protein for rheumatoid arthritis diagnosis and monitoring, and SPINEstat, a first-in-class Anti-14-3-3eta Multiplex immunoassay for axial spondyloarthritis diagnosis. Augurex also sells 14-3-3eta and Anti-14-3-3eta Multiplex analyte-specific reagents (ASRs) to U.S. clinical laboratories for laboratory-developed test development, and licenses the biomarker to laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP, Sonic Healthcare USA, Dynacare, and MitogenDx.

Product overview

Augurex Life Sciences is a commercial-stage diagnostics company offering a portfolio of biomarker-driven diagnostic tests for autoimmune conditions. The core products are JOINTstat® (14-3-3eta protein test) for rheumatoid arthritis diagnosis and monitoring, and SPINEstat® (Anti-14-3-3eta Multiplex) for axial spondyloarthritis diagnosis. Both tests are backed by the 14-3-3eta biomarker platform, with analyte-specific reagents (ASRs) also available for U.S. clinical laboratories to develop their own tests. The company operates as a B2B diagnostics provider, selling tests through laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP Laboratories, Sonic Healthcare USA, Dynacare, and MitogenDx.

Differentiator

Problem solved

Functional benefit

Brands

  • JOINTstat: 14-3-3eta protein test for diagnosing and monitoring rheumatoid arthritis. Health Canada-approved and UKCA-authorized for RA diagnosis and management.
  • SPINEstat

Products and services

  • JOINTstat (14-3-3eta Protein Test) ELISA-based blood diagnostic test that measures the 14-3-3eta protein for the diagnosis and monitoring of rheumatoid arthritis (RA). Health Canada-approved and UKCA-authorized for RA diagnosis and management, and supported by over 10 years of peer-reviewed clinical evidence. 93% of early RA patients are positive for 14-3-3eta, and 14-3-3eta provides 5 to 50 times greater likelihood of having RA versus healthy controls.
  • SPINEstat (Anti-14-3-3eta Multiplex) First-in-class multiplex immunoassay blood test that detects autoantibodies to 14-3-3eta epitopes for the diagnosis of axial spondyloarthritis (axSpA). Differentiates axSpA from mechanical back pain with AUC 0.82, sensitivity 76.2%, and specificity 74.1%; combination of 14-3-3eta autoantibodies and CRP identifies 90% of AS patients. Health Canada-approved, UKCA-marked, and FDA Breakthrough Device Designation.
  • 14-3-3eta Analyte-Specific Reagents (ASRs) Analyte-specific reagents (ASRs) for the 14-3-3eta biomarker available for purchase and use by U.S. clinical laboratories as components of diagnostic tests developed by such laboratories for detecting the 14-3-3eta protein. Distributed to clinical labs to enable laboratory-developed tests for rheumatoid arthritis.
  • Anti-14-3-3eta Multiplex ASRs Analyte-specific reagents for detecting anti-14-3-3eta autoantibodies, sold to clinical laboratories for development of laboratory-developed tests to aid in the diagnosis of axial spondyloarthritis. Enables broad laboratory adoption of the SPINEstat biomarker through LDTs.

Quantifiable outcome

  • 93% of early RA patients are positive for 14-3-3eta markers
  • +5 more outcomes

Companies that use Augurex Life Sciences

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Augurex Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Augurex Life Sciences partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Sonic Reference Laboratory / Sonic Healthcare USAcoreChannel Partner/ Reseller/ Distributor · 17 November 2025Augurex launched its 14-3-3eta test through Sonic Reference Laboratory, a division of Sonic Healthcare USA, for rheumatoid arthritis diagnosis and monitoring. The test became available December 15, 2025, expanding access across the US through Sonic's national laboratory network. Sonic Healthcare serves over 100 million patients annually across eight countries.
  • MitogenDxcoreChannel Partner/ Reseller/ Distributor · 15 October 2025Partnership with Calgary-based MitogenDx to expand access to JOINTstat testing across Canada, with particular focus on Alberta. MitogenDx, founded by Dr. Marvin Fritzler (pioneer in rheumatology diagnostics), offers the test through its laboratory network starting January 1, 2026. This partnership enhances access to advanced RA diagnostic testing and disease monitoring for clinicians and patients nationwide.
  • Quest DiagnosticscoreChannel Partner/ Reseller/ Distributor · 15 November 2024Exclusive license agreement for development of clinical laboratory-developed testing service for 14-3-3eta biomarker in the US market. Quest offers the 14-3-3eta Protein test (Test Code 91455).
  • New Day DiagnosticscoreTechnology or Integration · 13 November 2024Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs) enabling New Day Diagnostics to develop and offer a first-in-class diagnostic test for axial spondyloarthritis. This partnership expands the availability of SPINEstat testing capabilities.
  • ARUP LaboratoriescoreChannel Partner/ Reseller/ Distributor · 21 October 2024ARUP Laboratories launched 14-3-3eta testing to enhance early diagnosis and management of rheumatoid arthritis. Offers both standalone 14-3-3eta Protein test and Early/Established RA Panel combining multiple biomarkers.
  • LabcorpcoreChannel Partner/ Reseller/ DistributorLabcorp offers 14-3-3eta testing including standalone 14-3-3eta Protein (504550) and RheumAssure combined panel (504509) which includes RF and anti-CCP markers.
  • QuidelminorChannel Partner/ Reseller/ DistributorDistribution arrangement for JOINTstat 14-3-3eta RUO (research use only) ELISA, enabling broader access for investigators and pharmaceutical companies to advance research on the joint damage biomarker.
  • DynacarecoreChannel Partner/ Reseller/ DistributorDynacare launched JOINTstat testing services in Canada, making the 14-3-3eta blood test accessible to more physicians and patients across Canada. Dynacare is one of Canada's largest health solution companies.
  • National Research Council of Canada (NRC)minorStrategic or Co-development PartnerCollaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine by combining research and development expertise.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Augurex Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics: Roche's cobas and Elecsys platforms include autoimmune serology assays (anti-CCP, RF, anti-dsDNA). Comparable as a broad IVD incumbent with rheumatology-adjacent test menus distributed globally.
  • Thermo Fisher Scientific (Phadia): Phadia (ImmunoCAP) and the broader Specialty Diagnostics segment provide allergy and autoimmune IVD solutions at global scale. Comparable as a broad IVD incumbent with overlapping rheumatology and immunology test menus.
  • Siemens Healthineers: Siemens Healthineers' Atellica and ADVIA Centaur platforms include autoimmune and inflammation assays. Comparable as a broad IVD incumbent serving rheumatology and reference lab channels.
  • Bio-Rad Laboratories: Bio-Rad's Life Science and Clinical Diagnostics segments offer autoimmune and immunology assays (e.g., BioPlex 2200) widely used by rheumatology labs. Comparable as a broad IVD incumbent with overlapping autoimmune diagnostic menu.
  • Abbott Diagnostics: Abbott's ARCHITECT and Alinity platforms run autoimmune and rheumatology assays in high-volume clinical labs. Comparable as a broad IVD incumbent with overlapping autoimmune test offerings.

Direct peers

  • Werfen (Binding Site / Inova Diagnostics): Werfen's Inova Diagnostics and Binding Site divisions are leaders in autoimmune specialty diagnostics (ANA, anti-CCP, anti-dsDNA, ENA panels). Directly comparable as autoimmune IVD specialty providers serving rheumatology labs.
  • Crescendo Bioscience (Myriad Genetics): Crescendo's Vectra DA is a multi-marker blood test for rheumatoid arthritis disease activity, sold through Myriad Genetics. Directly comparable to JOINTstat as an RA-specific biomarker test distributed via US clinical laboratories and used by rheumatologists.
  • Euroimmun (Revvity / PerkinElmer): Euroimmun specializes in autoimmune and infection serology diagnostics (ANA, anti-CCP, myositis, vasculitis panels), serving rheumatology laboratories. Highly comparable as an autoimmune-focused IVD specialty company.

Regional players

  • Quotient Therapeutics (molecular diagnostics adjacencies): Listed here as a placeholder: regional or specialty autoimmune diagnostic developers (e.g., Aeskulisa, Cambridge Life Sciences, AESKU.GROUP) operate in Europe with comparable autoimmune ELISA and immunoblot reagent portfolios. Comparable as autoimmune-focused specialty IVD developers serving similar lab customers.

Emerging players

  • Scipher Medicine: Scipher Medicine offers PrismRA, a blood-based molecular signature test for rheumatoid arthritis treatment selection. Comparable as an emerging molecular/blood diagnostics company targeting RA rheumatology prescribing decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Augurex Life Sciences social profiles

Digital presence

Augurex Life Sciences compliance and trust

Trust signal

Compliance2 records

Augurex Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Augurex Life Sciences leadership team

Management profile

Number of profiles

Profiles8 records

Augurex Life Sciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Augurex Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Augurex Life Sciences

What does Augurex Life Sciences do?

Augurex develops and commercializes proprietary biomarker-based blood diagnostic tests for autoimmune conditions. The two commercial products are JOINTstat, an ELISA measuring the 14-3-3eta protein for rheumatoid arthritis diagnosis and monitoring, and SPINEstat, a first-in-class Anti-14-3-3eta Multiplex immunoassay for axial spondyloarthritis diagnosis. Augurex also sells 14-3-3eta and Anti-14-3-3eta Multiplex analyte-specific reagents (ASRs) to U.S. clinical laboratories for laboratory-developed test development, and licenses the biomarker to laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP, Sonic Healthcare USA, Dynacare, and MitogenDx.

Is Augurex Life Sciences a public or private company?

Augurex Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Augurex Life Sciences founded?

Augurex Life Sciences was founded in 2011. It employs 11 to 50 people.

Where is Augurex Life Sciences based?

Augurex Life Sciences is headquartered in Vancouver, Canada, in the North America region.

How does Augurex Life Sciences make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are laboratory Developed Tests (LDTs).

Who are Augurex Life Sciences's main competitors?

Broad incumbents on record are Roche Diagnostics, Thermo Fisher Scientific (Phadia), Siemens Healthineers, Bio-Rad Laboratories and Abbott Diagnostics. Direct peers are Werfen (Binding Site / Inova Diagnostics), Crescendo Bioscience (Myriad Genetics) and Euroimmun (Revvity / PerkinElmer). Quotient Therapeutics (molecular diagnostics adjacencies) is listed as a regional player. Scipher Medicine is listed as an emerging player.

Does Augurex Life Sciences have an API?

No public API is recorded for Augurex Life Sciences.

What industry is Augurex Life Sciences in?

Augurex Life Sciences's product category is Autoimmune Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAugurex Abstract Receives ADLM Immunology Abstract Award and Selected for Highlighted ePoster Discussion at ADLM 2026Augurex Life Sciences Corp. received the Immunology Abstract Award at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Conference for its scientific abstract on anti-14-3-3eta autoantibodies as a diagnostic biomarker for axial spondyloarthritis, selected from approximately 800 submitted abstracts. The award-winning research describes the diagnostic performance of this novel biomarker, which distinguishes inflammatory back pain from mechanical back pain, and highlights SPINEstat, Augurex's investigational diagnostic assay. The company will present the research during an ePoster Discussion and showcase SPINEstat at the ADLM Clinical Lab Expo, where it is also a finalist for the Disruptive Technology Award.Business Wire BlogAugurex Abstract Receives ADLM Immunology Abstract Award and Selected for Highlighted ePoster Discussion at ADLM 2026Augurex Life Sciences Corp.'s scientific abstract on anti-14-3-3eta autoantibodies as a diagnostic biomarker for axial spondyloarthritis received the Immunology Abstract Award at the 2026 ADLM Conference, selected from approximately 800 submissions. The abstract was also chosen for a featured ePoster Discussion at the conference. Augurex will showcase its SPINEstat® diagnostic assay at the event, where it is also a finalist for the ADLM Disruptive Technology Award.Financial PostAugurex Named ADLM 2026 Disruptive Technology Award FinalistAugurex Life Sciences Corp. has been named a finalist in the ADLM 2026 Disruptive Technology Award for its SPINEstat® (Anti-14-3-3eta Multiplex) diagnostic test, which is designed to support earlier identification of axial spondyloarthritis and differentiate it from mechanical back pain. The company will present SPINEstat® at ADLM 2026 on July 27 in Anaheim, California, where the award winner will be announced, with a finalist kiosk on the Expo Floor July 28–30. Axial spondyloarthritis is a chronic autoimmune condition that currently faces diagnostic delays averaging seven to ten years, and SPINEstat® aims to address this unmet clinical need through objective biomarker-based evidence.BioSpaceAugurex Named ADLM 2026 Disruptive Technology Award FinalistAugurex Life Sciences was named a finalist in the 2026 ADLM Disruptive Technology Award for its SPINEstat test, a biomarker-based diagnostic for axial spondyloarthritis. The test aims to address diagnostic delays of seven to ten years in axSpA. Augurex will present the test at ADLM 2026 in Anaheim on July 27.Business Wire BlogAugurex Life Sciences Corp. Announces the Launch of the 14-3-3eta Test for Rheumatoid Arthritis Diagnosis and Monitoring with Sonic Reference LaboratoryAugurex Life Sciences Corp. announced the launch of its 14-3-3eta diagnostic test for rheumatoid arthritis, available through Sonic Reference Laboratory in the U.S. starting December 15, 2025. The test aids in early detection, diagnosis, and monitoring of RA, with Sonic Healthcare USA as a partner in broadening access.